外泌体：治疗进展的创新囊泡

Exosomes are nanometer- sizedmembrane vesicles released bycells for cell-to-cell communication,delivering various molecules —including but not limited to DNA,RNA, proteins, and lipids. Exosome innovation is centered onthe development of these vesiclesas diagnostics and as vehicles toincrease and improve options forsuccessful treatment delivery. The activity attributed to mixed celltreatments that include or excreteexosomes may prove to be dependenton exosomes for all or part of theiractivity, similar to deramiocel. Exosomes have the potentialto impact a wide range oftherapeutic areas, though mosttreatments are still in preclinical orearly development stages. New endeavors in engineeredexosomes and "exosome-like" deliveryvesicles enhance the possibilities forfuture treatment successes withprecision nanotherapeutics. Drug trends by global status The drug disease landscape reflects the extensive commitment to exosome exploration as treatments as well as multiple otherroles to establish disease intelligence (e.g., sources for biomarkers, elucidators of disease processes and prognosis, andtreatment transporters. The majority are still preclinical with development driven by small specialty pharma or biotech companies. PreclinicalPhaseIIClinical TrialSuspendedPhaseIClinical Trial Total trials by therapeutic area Exosome-associated studies span all therapeutic areas. Oncology holds the highest share of trial activities.Ongoing trials are exploring the multiple roles that exosomes can take. – Oncology– Autoimmune/Inflammation– Infectious Disease– CNS– Metabolic/Endocrinology– Cardiovascular– Ophthalmology– Genitourinary– Vaccines (Infectious Disease)69353026119741 Trialtrove,February2025 Consensus forecasts for exosome-based treatments Deramiocel is an exosome-dependent cell treatment in Phase III for Duchenne muscular dystrophy (DMD). Cell-releasedexosomes act to reduce inflammation, thus preventing heart failure, the leading cause of death in DMD. Based on this treatmentexample, other mixed cell treatments may prove to be more exosome-dependent than they have yet to be realized. Anticipated success for deramiocel supports the competitive forecast shared below. Multiple listings of drugs in the table indicatea partnership agreement in which more than one company anticipates financial gain. For deramiocel, Nippon Shinyaku andCapricor Therapeutics are in a partnership for commercialization and distribution. Already looking ahead… While development of naturally occurring and therapeutic exosomes is still in its infancy,innovative progress is underway, e.g., optimizing release of exosome contents inside receivingcells and optimizing exosome-like vesicles to ease challenges experienced with exosomepurification/consistency/storage. Possibilities are limitless in this expanding landscape,leading to new hopes for disease treatments across all therapeutic areas. LEARN MORE To learn more about the advantages we can deliver to your company, please visit: Citeline.com or email: info@Citeline.com Copyright ©2025 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in Englandand Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ